Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1021/acsptsci.0c00071 http://scihub22266oqcxt.onion/10.1021/acsptsci.0c00071 33062949!7469881!33062949     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33062949&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       ACS+Pharmacol+Transl+Sci 2020 ; 3 (5): 790-800 Nephropedia Template TP {{tp|p=33062949|t=2020. Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19 |pdf=|usr=}}{{33062949}} gab.com Text Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19 JO: ACS Pharmacol Transl Sci http://www.kidney.de/pget.php?&tw=1&pmid=33062949 #FOAvip Coronavirus is one of the causative agents for multiple human respiratory illnesses. A novel coronavirus, similar to the one that caused severe acute respiratory syndrome (SARS) in 2003, was identified as the cause of the current pandemic of coronavirus disease (COVID-19), which was first reported in late December 2019 in Wuhan, China. Since then, this novel coronavirus has spread across the globe, with most identified COVID-19 cases and fatalities occurring in the United States. In this Perspective, we discuss coronavirus pathogenicity, conventional antiviral therapies, prophylactic strategies, and novel treatment strategies for COVID-19. We highlight the application of CRISPR technology as an emerging pan-antiviral therapy. We also discuss the challenges of in vivo delivery of CRISPR components and propose novel approaches to achieve selective delivery exclusively into SARS-CoV-2-infected cells with high efficiency by hijacking the surface proteins of SARS-CoV-2. Twit Text FOAVip Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19 ????ACS Pharmacol Transl Sci http://www.kidney.de/pget.php?&tw=1&pmid=33062949 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33062949 #FOAvip English Wikipedia <ref>{{Cite pmid|33062949}}</ref> Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19 #MMPMID33062949 Nalawansha DA; Samarasinghe KTG ACS Pharmacol Transl Sci 2020[Oct]; 3 (5): 790-800 PMID33062949show ga Coronavirus is one of the causative agents for multiple human respiratory illnesses. A novel coronavirus, similar to the one that caused severe acute respiratory syndrome (SARS) in 2003, was identified as the cause of the current pandemic of coronavirus disease (COVID-19), which was first reported in late December 2019 in Wuhan, China. Since then, this novel coronavirus has spread across the globe, with most identified COVID-19 cases and fatalities occurring in the United States. In this Perspective, we discuss coronavirus pathogenicity, conventional antiviral therapies, prophylactic strategies, and novel treatment strategies for COVID-19. We highlight the application of CRISPR technology as an emerging pan-antiviral therapy. We also discuss the challenges of in vivo delivery of CRISPR components and propose novel approaches to achieve selective delivery exclusively into SARS-CoV-2-infected cells with high efficiency by hijacking the surface proteins of SARS-CoV-2. ?Double-Barreled CRISPR Technology as a Novel Treatment Strategy For CO(epmc).pdf DeepDyve Pubget Overpricing